Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Susuxiaoer Zhike Granules is a Traditional Chinese Medicine (TCM) therapeutic developed by Wuhan Pharmaceutical Valley Technology Development for the treatment of pediatric common cold and acute cough. Specifically indicated for the "wind-cold" pattern in TCM diagnostics, the formulation aims to alleviate cough symptoms and shorten the overall course of the illness in children. The drug is administered orally as granules. It has been evaluated in a randomized, double-blind Phase II clinical trial in China (CTR20192628) to assess the efficacy and safety of various dose levels compared to placebo or standard care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Susuxiaoer Zhike Granules.